Compare Atlassian Corporation PLC (TEAM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Zimmer Biomet Holdings Inc — how do they compare? Atlassian Corporation PLC trades at $206.79 (market cap $51.53B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Atlassian Corporation PLC is far larger — about 3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TEAM | ZBH | |
|---|---|---|
Market Cap | $51.53B | $16.95B |
Volume | 2,904,511 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $203.57 | $103.98 |
52-Week Low | $57.15 | $79.58 |
Typical Hold Time | 65 Days | 89 Days |
Enterprise Value | $51.52B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $206.79, up 5.68% with strong bullish momentum. The stock shows robust technical strength with moving averages signaling buy and price above key resistance levels. Fundamentally, revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable. Recent earnings beats and strong analyst consensus (69.77% buy ratings) support the positive sentiment, while AI-driven product adoption and cloud migration provide growth catalysts.
The outlook remains positive with AI adoption and cloud growth driving momentum, though valuation metrics appear stretched with negative profitability. Key risks include high P/S ratio (8.06), competitive pressures, and execution challenges in maintaining growth trajectory. The consensus price target of $191.16 suggests potential downside from current levels despite strong fundamental improvements.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
